Target family: Voltage-gated calcium channels  (Ca<sub>V</sub>) (type: vgic)
Target: Ca<sub>v</sub>3.2

Ligand: 3β-OH (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 5.519999980926514 pIC50
Reference (Journal): A neurosteroid analogue with T-type calcium channel blocking properties is an effective hypnotic, but is not harmful to neonatal rat brain.
Published in: Br J Anaesth

Ligand: ABT-639 (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats.
Published in: Biochem Pharmacol

Ligand: ACT-709478 (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
Published in: J Med Chem

Ligand: anandamide (Metabolite)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 6.5 pIC50
Reference (Journal): Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.
Published in: EMBO J

Ligand: efonidipine (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: Japan (1995)
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
Published in: Pharmacology

Ligand: flunarizine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 5.449999809265137 pIC50
Reference (Journal): Differential inhibition of T-type calcium channels by neuroleptics.
Published in: J Neurosci

Ligand: kurtoxin (Peptide)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin.
Published in: Nat Neurosci

Ligand: kurtoxin (Peptide)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels.
Published in: J Neurosci

Ligand: mibefradil (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (1997)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Mibefradil block of cloned T-type calcium channels.
Published in: J Pharmacol Exp Ther

Ligand: ML218 (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 6.5 pIC50
Reference (Journal): The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease.
Published in: ACS Chem Neurosci

Ligand: Ni2+ (Inorganic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Nickel block of three cloned T-type calcium channels: low concentrations selectively block alpha1H.
Published in: Biophys J

Ligand: pimozide (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Discovery of pimozide derivatives as novel T-type calcium channel inhibitors with little binding affinity to dopamine D<sub>2</sub> receptors for treatment of somatic and visceral pain.
Published in: Eur J Med Chem

Ligand: pimozide (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): Differential inhibition of T-type calcium channels by neuroleptics.
Published in: J Neurosci

Ligand: suvecaltamide (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.09000015258789 pIC50
Reference (Journal): Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers.
Published in: J Med Chem

Ligand: TTA-A2 (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects.
Published in: Pain

Ligand: TTA-P2 (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinociceptive agent.
Published in: Mol Pharmacol

Ligand: Z944 (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures.
Published in: Sci Transl Med